Ontology highlight
ABSTRACT:
SUBMITTER: Faysal KMR
PROVIDER: S-EPMC10863983 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature
Faysal K M Rifat KMR Walsh James C JC Renner Nadine N Márquez Chantal L CL Shah Vaibhav B VB Tuckwell Andrew J AJ Christie Michelle P MP Parker Michael W MW Turville Stuart G SG Towers Greg J GJ James Leo C LC Jacques David A DA Böcking Till T
eLife 20240213
The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use. Here, we investigate the effect of lenacapavir on HIV capsid stability and uncoating. We employ a single particle approach that simultaneously measures capsid content release and lattice persistence. We demonstrate that lenacapavir's potent antiviral activity is predominantly due to lethal hyperstabilisation of the ...[more]